Alembic receives USFDA final approval for Ticagrelor Tablets, 90 mg and tentative approval for Ticagrelor Tablets, 60 mg
Ticagrelor tablets are indicated for to reduce the risk of cardiovascular death and myocardial infarction,
Ticagrelor tablets are indicated for to reduce the risk of cardiovascular death and myocardial infarction,
Niacin is indicated to reduce elevated total cholesterol, LDL cholesterol, apolipoprotein B and triglycerides (TG)
Tolvaptan is indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease
A new weapon in the global fight against malaria
Access to NIPT, TB and Rare Disease diagnostics to benefit thousands of patients nationwide
The system is powered by advanced imaging innovations such as Amber-red Color Imaging, Triple Noise Reduction, and Extended Dynamic Range Image Processing
Over 1500 stakeholders representing food businesses, packaging industries, recycling associations, regulatory bodies, environmental organizations, consumer groups, farmer groups, government departments participated in the consultation
SmartTrack aims to reduce the need for clinical studies in generic drug product approvals
Zydus MedTech gets rights to market the innovative Transcatheter Aortic Valve Implantation (TAVI) technology in India, Europe and other select markets
Rising demands and advancements in eye care drive growth
Subscribe To Our Newsletter & Stay Updated